Regulatory T Cells in Immune Homeostasis: Mechanisms of Peripheral Tolerance and Immunoregulation

References

[1] R. K. Gershon and K. Kondo, “Infectious immunological tolerance,” Immunology, vol. 21, no. 6, pp. 903–914, 1971.

[2] S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, and M. Toda, “Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25): Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases,” The Journal of Immunology, vol. 155, no. 3, pp. 1151–1164, 1995.

[3] C. L. Bennett, J. Christie, F. Ramsdell, M. E. Brunkow, P. J. Ferguson, L. Whitesell, T. E. Kelly, F. T. Saulsbury, P. F. Chance, and H. D. Ochs, “The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3,” Nature Genetics, vol. 27, no. 1, pp. 20–21, 2001. Nature

[4] D. A. A. Vignali, L. W. Collison, and C. J. Workman, “How regulatory T cells work,” Nature Reviews Immunology, vol. 8, no. 7, pp. 523–532, 2008. Nature

[5] S. Dikiy and A. Y. Rudensky, “Principles of regulatory T cell function,” Immunity, vol. 56, no. 2, pp. 240–255, 2023. ScienceDirect

[6] A. Kaminski, F. T. Hager, L. Kopplin, F. Ticconi, A. Leufgen, E. Vendelova, L. Rüttger, G. Gasteiger, V. Cerovic, W. Kastenmüller, O. Pabst, and M. Ugur, “Resident regulatory T cells reflect the immune history of individual lymph nodes,” Science Immunology, vol. 8, no. 89, Art. no. eadj5789, 2023. Science

[7] P. Grover, P. N. Goel, and M. I. Greene, “Regulatory T Cells: Regulation of Identity and Function,” Frontiers in Immunology, vol. 12, Art. no. 750542, 2021. Frontiers

[8] M. Arjomandnejad, A. L. Kopec, and A. M. Keeler, “CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications,” Biomedicines, vol. 10, no. 2, Art. no. 287, 2022. MDPI

[9] F. Shirafkan, L. Hensel, and K. Rattay, “Immune tolerance and the prevention of autoimmune diseases essentially depend on thymic tissue homeostasis,” Frontiers in Immunology, vol. 15, Art. no. 1339714, 2024. Frontiers

[10] S. Z. Josefowicz, L. F. Lu, and A. Y. Rudensky, “Regulatory T cells: mechanisms of differentiation and function,” Annual Review of Immunology, vol. 30, pp. 531–564, 2012. Annual Reviews

[11] A. M. Bilate and J. J. Lafaille, “Induced CD4⁺Foxp3⁺ regulatory T cells in immune tolerance,” Annual Review of Immunology, vol. 30, pp. 733–758, 2012. Annual Reviews

[12] W. Chen, W. Jin, N. Hardegen, K.-J. Lei, L. Li, N. Marinos, G. McGrady, and S. M. Wahl, “Conversion of peripheral CD4⁺CD25⁻ naive T cells to CD4⁺CD25⁺ regulatory T cells by TGF-β induction of transcription factor Foxp3,” The Journal of Experimental Medicine, vol. 198, no. 12, pp. 1875–1886, 2003. JEM

[13] W. Chen, “TGF-β Regulation of T Cells,” Annual Review of Immunology, vol. 41, pp. 483–512, 2023. Annual Reviews

[14] T. R. Malek and I. Castro, “Interleukin-2 receptor signaling: At the interface between tolerance and immunity,” Immunity, vol. 33, no. 2, pp. 153–165, 2010. ScienceDirect

[15] J. L. Coombes, K. R. R. Siddiqui, C. V. Arancibia-Cárcamo, J. Hall, C.-M. Sun, Y. Belkaid, and F. Powrie, “A functionally specialized population of mucosal CD103⁺ dendritic cells induces Foxp3⁺ regulatory T cells via a TGF-β- and retinoic acid-dependent mechanism,” Journal of Experimental Medicine, vol. 204, no. 8, pp. 1757–1764, 2007. JEM

[16] Y. Furusawa, Y. Obata, S. Fukuda, T. A. Endo, G. Nakato, D. Takahashi, Y. Nakanishi, C. Uetake, K. Kato, T. Kato, M. Takahashi, N. N. Fukuda, S. Murakami, E. Miyauchi, S. Hino, K. Atarashi, S. Onawa, Y. Fujimura, T. Lockett, J. M. Clarke, D. L. Topping, M. Tomita, S. Hori, O. Ohara, T. Morita, H. Koseki, J. Kikuchi, K. Honda, K. Hase, and H. Ohno, “Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells,” Nature, vol. 504, no. 7480, pp. 446–450, 2013. Nature

[17] N. Arpaia, C. Campbell, X. Fan, S. Dikiy, J. van der Veeken, P. deRoos, H. Liu, J. R. Cross, K. Pfeffer, P. J. Coffer, and A. Y. Rudensky, “Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation,” Nature, vol. 504, no. 7480, pp. 451–455, 2013. Nature

[18] S. Z. Josefowicz, L. F. Lu, and A. Y. Rudensky, “Regulatory T cells: mechanisms of differentiation and function,” Annual Review of Immunology, vol. 30, pp. 531–564, 2012. Annual Reviews

[19] W. Chen, W. Jin, N. Hardegen, K.-J. Lei, L. Li, N. Marinos, G. McGrady, and S. M. Wahl, “Conversion of peripheral CD4⁺CD25⁻ naive T cells to CD4⁺CD25⁺ regulatory T cells by TGF-β induction of transcription factor Foxp3,” The Journal of Experimental Medicine, vol. 198, no. 12, pp. 1875–1886, 2003. JEM

[20] J. A. Bluestone and Q. Tang, “Treg cells—the next frontier of cell therapy,” Science, vol. 362, no. 6411, pp. 154–155, 2018. Science

[21] S. Floess, J. Freyer, C. Siewert, U. Baron, S. Olek, J. Polansky, K. Schlawe, H.-D. Chang, T. Bopp, E. Schmitt, S. Klein-Hessling, E. Serfling, and A. Hamann, “Epigenetic control of the foxp3 locus in regulatory T cells,” PLoS Biology, vol. 5, no. 2, Art. no. e38, 2007. PLOS

[22] J. K. Polansky, K. Kretschmer, J. Freyer, S. Floess, A. Garbe, U. Baron, S. Olek, A. Hamann, and H. von Boehmer, “DNA methylation controls Foxp3 gene expression,” European Journal of Immunology, vol. 40, no. 7, pp. 1835–1844, 2010. Wiley

[23] S. Dikiy and A. Y. Rudensky, “Principles of regulatory T cell function,” Immunity, vol. 56, no. 2, pp. 240–255, 2023. ScienceDirect

[24] M. R. Vieyra-Lobato, J. Vela-Ojeda, L. Montiel-Cervantes, R. López-Santiago, and M. C. Moreno-Lafont, “Description of CD8⁺ Regulatory T Lymphocytes and Their Specific Intervention in Graft-versus-Host and Infectious Diseases, Autoimmunity, and Cancer,” Journal of Immunology Research, vol. 2018, Art. ID 3758713, 2018. Wiley

[25] H. Jiang and L. Chess, “Regulation of immune responses by T cells,” New England Journal of Medicine, vol. 354, no. 11, pp. 1166–1176, 2006. NEJM

[26] M. Panduro, C. Benoist, and D. Mathis, “Tissue Tregs,” Annual Review of Immunology, vol. 34, pp. 609–633, 2016. Annual Reviews

[27] A. Kaminski, F. T. Hager, L. Kopplin, F. Ticconi, A. Leufgen, E. Vendelova, L. Rüttger, G. Gasteiger, V. Cerovic, W. Kastenmüller, O. Pabst, and M. Ugur, “Resident regulatory T cells reflect the immune history of individual lymph nodes,” Science Immunology, vol. 8, no. 89, Art. no. eadj5789, 2023. Science

[28] M. Feuerer, L. Herrero, D. Cipolletta, A. Naaz, J. Wong, A. Nayer, J. Lee, A. B. Goldfine, C. Benoist, S. Shoelson, and D. Mathis, “Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters,” Nature Medicine, vol. 15, no. 8, pp. 930–939, 2009. Nature

[29] D. Cipolletta, M. Feuerer, A. Li, N. Kamei, J. Lee, S. E. Shoelson, C. Benoist, and D. Mathis, “PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells,” Nature, vol. 486, no. 7404, pp. 549–553, 2012. Nature

[30] N. Ali, B. Zirak, R. S. Rodriguez, M. L. Pauli, H.-A. Truong, K. Lai, R. Ahn, K. Corbin, M. M. Lowe, T. C. Scharschmidt, K. Taravati, M. R. Tan, R. R. Ricardo-Gonzalez, A. Nosbaum, M. Bertolini, W. Liao, F. O. Nestle, R. Paus, and M. D. Rosenblum, “Regulatory T Cells in Skin Facilitate Epithelial Stem Cell Differentiation,” Cell, vol. 169, no. 6, pp. 1119–1129.e11, 2017. ScienceDirect

[31] E. Sefik, N. Geva-Zatorsky, S. Oh, L. Konnikova, D. Zemmour, A. M. McGuire, D. Burzyn, A. Ortiz-Lopez, M. Lobera, J. Yang, S. Ghosh, A. Earl, S. B. Snapper, R. Jupp, D. Kasper, D. Mathis, C. Benoist, and R. J. Xavier, “Individual intestinal symbionts induce a distinct population of RORγ⁺ regulatory T cells,” Science, vol. 349, no. 6251, pp. 993–997, 2015. Science

[32] N. Arpaia, J. A. Green, B. Moltedo, A. Arvey, S. Hemmers, S. Yuan, P. M. Treuting, and A. Y. Rudensky, “A Distinct Function of Regulatory T Cells in Tissue Protection,” Cell, vol. 162, no. 5, pp. 1078–1089, 2015. ScienceDirect

[33] G. Plitas, C. Konopacki, K. Wu, P. D. Bos, M. Morrow, E. V. Putintseva, D. M. Chudakov, and A. Y. Rudensky, “Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer,” Immunity, vol. 45, no. 5, pp. 1122–1134, 2016. ScienceDirect

[34] J. B. Wing, A. Tanaka, and S. Sakaguchi, “Human FOXP3⁺ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer,” Immunity, vol. 50, no. 2, pp. 302–316, 2019. ScienceDirect

[35] S. Hori, T. Nomura, and S. Sakaguchi, “Control of regulatory T cell development by the transcription factor Foxp3,” Science, vol. 299, no. 5609, pp. 1057–1061, 2003. Science

[36] M. E. Brunkow, E. W. Jeffery, K. A. Hjerrild, B. Paeper, L. B. Clark, S.-A. Yasayko, J. E. Wilkinson, D. Galas, S. F. Ziegler, and F. Ramsdell, “Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse,” Nature Genetics, vol. 27, no. 1, pp. 68–73, 2001. Nature

[37] C. L. Bennett, J. Christie, F. Ramsdell, M. E. Brunkow, P. J. Ferguson, L. Whitesell, T. E. Kelly, F. T. Saulsbury, P. F. Chance, and H. D. Ochs, “The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3,” Nature Genetics, vol. 27, no. 1, pp. 20–21, 2001. Nature

[38] D. Rudra, P. deRoos, A. Chaudhry, R. E. Niec, A. Arvey, R. M. Samstein, C. Leslie, S. A. Shaffer, D. R. Goodlett, and A. Y. Rudensky, “Transcription factor Foxp3 and its protein partners form a complex regulatory network,” Nature Immunology, vol. 13, no. 10, pp. 1010–1019, 2012. Nature

[39] M. A. Burchill, J. Yang, C. Vogtenhuber, B. R. Blazar, and M. A. Farrar, “IL-2 receptor β-dependent STAT5 activation is required for the development of Foxp3⁺ regulatory T cells,” The Journal of Immunology, vol. 178, no. 1, pp. 280–290, 2007. Journal of Immunology

[40] W. Chen, W. Jin, N. Hardegen, K.-J. Lei, L. Li, N. Marinos, G. McGrady, and S. M. Wahl, “Conversion of peripheral CD4⁺CD25⁻ naive T cells to CD4⁺CD25⁺ regulatory T cells by TGF-β induction of transcription factor Foxp3,” Journal of Experimental Medicine, vol. 198, no. 12, pp. 1875–1886, 2003. JEM

[41] G. M. Delgoffe, T. P. Kole, Y. Zheng, P. E. Zarek, K. L. Matthews, B. Xiao, P. F. Worley, S. C. Kozma, J. D. Powell, and T. J. Curiel, “The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment,” Immunity, vol. 30, no. 6, pp. 832–844, 2009. ScienceDirect

[42] N. Ohkura, M. Hamaguchi, H. Morikawa, K. Sugimura, A. Tanaka, Y. Ito, M. Osaki, Y. Tanaka, R. Yamashita, N. Nakano, J. Huehn, H. J. Fehling, T. Sparwasser, K. Nakai, and S. Sakaguchi, “T Cell Receptor Stimulation-Induced Epigenetic Changes and Foxp3 Expression Are Independent and Complementary Events Required for Regulatory T Cell Development,” Immunity, vol. 37, no. 5, pp. 785–799, 2013. ScienceDirect

[43] R. M. Samstein, A. Arvey, S. Z. Josefowicz, X. Peng, A. Reynolds, R. Sandstrom, S. Neph, P. Sabo, J. M. Kim, W. Liao, M. O. Li, C. Leslie, J. A. Stamatoyannopoulos, and A. Y. Rudensky, “Foxp3 Exploits a Pre-existent Enhancer Landscape for Regulatory T Cell Lineage Specification,” Cell, vol. 151, no. 1, pp. 153–166, 2012. ScienceDirect

[44] S. Floess, J. Freyer, C. Siewert, U. Baron, S. Olek, J. Polansky, K. Schlawe, H.-D. Chang, T. Bopp, E. Schmitt, S. Klein-Hessling, E. Serfling, and A. Hamann, “Epigenetic control of the Foxp3 locus in regulatory T cells,” PLoS Biology, vol. 5, no. 2, Art. no. e38, 2007. PLOS

[45] J. K. Polansky, K. Kretschmer, J. Freyer, S. Floess, A. Garbe, U. Baron, S. Olek, A. Hamann, and H. von Boehmer, “DNA methylation controls Foxp3 gene expression,” European Journal of Immunology, vol. 40, no. 7, pp. 1835–1844, 2010. Wiley

[46] J. van Loosdregt, Y. Vercoulen, T. Guichelaar, Y. Y. J. Gent, J. M. Beekman, O. van Beekum, A. B. Brenkman, D. J. Hijnen, T. Mutis, E. Kalkhoven, B. J. Prakken, P. J. Coffer, and R. A. W. van Lier, “Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization,” Blood, vol. 115, no. 5, pp. 965–974, 2010. Blood

[47] L. Lu, J. Barbi, F. Pan, J. Yu, S. Parish, S. Chowdhury, Y. Wu, Y. Zheng, D. Pardoll, and F. Pan, “The forkhead transcription factor Foxp3 promotes DNA binding of NFAT by cooperative interaction,” Cell, vol. 139, no. 5, pp. 949–962, 2009.

[48] S. Kohlhaas, O. A. Garden, C. Scudamore, M. Turner, K. Okkenhaug, and E. Vigorito, “Cutting Edge: The Foxp3 target miR-155 contributes to the development of regulatory T cells,” The Journal of Immunology, vol. 182, no. 5, pp. 2578–2582, 2009. Journal of Immunology

[49] N. Ohkura, Y. Kitagawa, and S. Sakaguchi, “Development and maintenance of regulatory T cells,” Immunity, vol. 52, no. 1, pp. 30–41, 2020.

[50] X. Zhou, S. L. Bailey-Bucktrout, L. T. Jeker, and J. A. Bluestone, “Plasticity of CD4⁺ FoxP3⁺ T cells,” Current Opinion in Immunology, vol. 21, no. 3, pp. 281–285, 2009. ScienceDirect

[51] S. Hori, “FOXP3 as a master regulator of Treg cells,” Nature Reviews Immunology, vol. 21, no. 10, pp. 618–619, 2021. Nature

[52] E. Bettelli, Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, and V. K. Kuchroo, “Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells,” Nature, vol. 441, no. 7090, pp. 235–238, 2006. Nature

[53] M. Dominguez-Villar and D. A. Hafler, “Regulatory T cells in autoimmune disease,” Nature Immunology, vol. 19, no. 7, pp. 665–673, 2018. Nature

[54] M. A. Koch, G. Tucker-Heard, N. R. Perdue, J. R. Killebrew, K. B. Urdahl, and D. J. Campbell, “The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation,” Nature Immunology, vol. 10, no. 6, pp. 595–602, 2009. Nature

[55] Y. Zheng, A. Chaudhry, A. Kas, P. deRoos, J. M. Kim, T.-T. Chu, L. Corcoran, P. Treuting, U. Klein, and A. Y. Rudensky, “Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control TH2 responses,” Nature, vol. 458, no. 7236, pp. 351–356, 2009. Nature

[56] D. A. A. Vignali, L. W. Collison, and C. J. Workman, “How regulatory T cells work,” Nature Reviews Immunology, vol. 8, no. 7, pp. 523–532, 2008. Nature

[57] S. Dikiy and A. Y. Rudensky, “Principles of regulatory T cell function,” Immunity, vol. 56, no. 2, pp. 240–255, 2023. ScienceDirect

[58] D. A. A. Vignali, L. W. Collison, and C. J. Workman, “How regulatory T cells work,” Nature Reviews Immunology, vol. 8, no. 7, pp. 523–532, 2008. Nature

[59] R. Kühn, J. Löhler, D. Rennick, K. Rajewsky, and W. Müller, “Interleukin-10-deficient mice develop chronic enterocolitis,” Cell, vol. 75, no. 2, pp. 263–274, 1993. ScienceDirect

[60] W. Chen, “TGF-β Regulation of T Cells,” Annual Review of Immunology, vol. 41, pp. 483–512, 2023. Annual Reviews

[61] L. W. Collison, C. J. Workman, T. T. Kuo, K. Boyd, Y. Wang, K. M. Vignali, R. Cross, D. Sehy, R. S. Blumberg, and D. A. A. Vignali, “The inhibitory cytokine IL-35 contributes to regulatory T-cell function,” Nature, vol. 450, no. 7169, pp. 566–569, 2007. Nature

[62] C. Ye, H. Yano, C. J. Workman, and D. A. A. Vignali, “Interleukin-35: Structure, Function and Its Impact on Immune-Related Diseases,” Journal of Interferon & Cytokine Research, vol. 41, no. 11, pp. 391–406, 2021. Mary Ann Liebert

[63] L. S. K. Walker and D. M. Sansom, “The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses,” Nature Reviews Immunology, vol. 11, no. 12, pp. 852–863, 2011. Nature

[64] O. S. Qureshi, Y. Zheng, K. Nakamura, K. Attridge, C. Manzotti, E. M. Schmidt, J. Baker, L. E. Jeffery, S. Kaur, Z. Briggs, T. Z. Hou, C. E. Futter, G. Anderson, L. S. K. Walker, and D. M. Sansom, “Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4,” Science, vol. 332, no. 6029, pp. 600–603, 2011. Science

[65] N. Sobhani, D. R. Tardiel-Cyril, A. Davtyan, D. Generali, R. Roudi, and Y. Li, “CTLA-4 in Regulatory T Cells for Cancer Immunotherapy,” Cancers, vol. 13, no. 6, Art. no. 1440, 2021. MDPI

[66] “The diverse functions of the PD1 inhibitory pathway,” Nature Reviews Immunology, vol. 18, no. 3, pp. 153–167. Nature

[67] N. Joller, E. Lozano, P. R. Burkett, B. Patel, S. Xiao, C. Zhu, J. Xia, T. G. Tan, E. Sefik, V. Yajnik, A. H. Sharpe, F. J. Quintana, D. Mathis, C. Benoist, and V. K. Kuchroo, “Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses,” Immunity, vol. 40, no. 4, pp. 569–581, 2014. ScienceDirect

[68] C.-T. Huang, C. J. Workman, D. Flies, X. Pan, A. L. Marson, G. Zhou, E. L. Hipkiss, S. Ravi, J. Kowalski, H. I. Levitsky, J. D. Powell, D. M. Pardoll, and C. G. Drake, “Role of LAG-3 in regulatory T cells,” Immunity, vol. 21, no. 4, pp. 503–513, 2004. ScienceDirect

[69] P. Pandiyan, L. Zheng, S. Ishihara, J. Reed, and M. J. Lenardo, “CD4⁺CD25⁺Foxp3⁺ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4⁺ T cells,” Nature Immunology, vol. 8, no. 12, pp. 1353–1362, 2007. Nature

[70] S. Deaglio, K. M. Dwyer, W. Gao, D. Friedman, A. Usheva, A. Erat, J.-F. Chen, K. Enjyoji, J. Linden, M. Oukka, V. K. Kuchroo, T. B. Strom, and S. C. Robson, “Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression,” The Journal of Experimental Medicine, vol. 204, no. 6, pp. 1257–1265, 2007. JEM

[71] W. J. Grossman, J. W. Verbsky, W. Barchet, and M. Colonna, “Human T regulatory cells can use the perforin pathway to cause autologous target cell death,” Immunity, vol. 21, no. 4, pp. 589–601, 2004. ScienceDirect

[72] R. D. Michalek, V. A. Gerriets, S. R. Jacobs, A. N. Macintyre, N. J. MacIver, E. F. Mason, S. A. Sullivan, A. G. Nichols, and J. C. Rathmell, “Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4⁺ T Cell Subsets,” The Journal of Immunology, vol. 186, no. 6, pp. 3299–3303, 2011. Journal of Immunology

[73] A. Angelin, L. Gil-de-Gómez, S. Dahiya, J. Jiao, L. Guo, M. H. Levine, Z. Wang, W. J. Quinn III, P. K. Kopinski, L. Wang, T. Akimova, Y. Liu, T. R. Bhatti, R. Han, B. L. Laskin, J. A. Baur, I. A. Blair, D. C. Wallace, W. W. Hancock, and U. H. Beier, “Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments,” Cell Metabolism, vol. 25, no. 6, pp. 1282–1293.e7, 2017. ScienceDirect

[74] D. Howie, S. P. Cobbold, E. Adams, A. Ten Bokum, A. S. Necula, W. Zhang, H. Huang, D. J. Roberts, B. Thomas, S. S. Hester, M. Mayr, Y. Chernajovsky, H. Waldmann, and S. P. Cobbold, “Foxp3 drives oxidative phosphorylation and protection from lipotoxicity,” The Journal of Clinical Investigation, vol. 127, no. 11, pp. 4188–4202, 2017. JCI

[75] N. M. Chapman, M. R. Boothby, and H. Chi, “Metabolic coordination of T cell quiescence and activation,” Nature Reviews Immunology, vol. 20, no. 1, pp. 55–70, 2020. Nature

[76] E. L. Pearce, M. C. Poffenberger, C.-H. Chang, and R. G. Jones, “Fueling immunity: Insights into metabolism and lymphocyte function,” Science, vol. 342, no. 6155, Art. no. 1242454, 2013. Science

[77] A. Angelin, L. Gil-de-Gómez, S. Dahiya, J. Jiao, L. Guo, M. H. Levine, Z. Wang, W. J. Quinn III, P. K. Kopinski, L. Wang, T. Akimova, Y. Liu, T. R. Bhatti, R. Han, B. L. Laskin, J. A. Baur, I. A. Blair, D. C. Wallace, W. W. Hancock, and U. H. Beier, “Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments,” Cell Metabolism, vol. 25, no. 6, pp. 1282–1293.e7, 2017. ScienceDirect

[78] S. E. Weinberg, B. D. Singer, and E. M. Steinert, “Mitochondrial complex III is essential for suppressive function of regulatory T cells,” Nature, vol. 565, no. 7740, pp. 495–499, 2019. Nature

[79] N. M. Chapman, M. R. Boothby, and H. Chi, “Metabolic coordination of T cell quiescence and activation,” Nature Reviews Immunology, vol. 20, no. 1, pp. 55–70, 2020. Nature

[80] D. Cipolletta, M. Feuerer, A. Li, N. Kamei, J. Lee, S. E. Shoelson, C. Benoist, and D. Mathis, “PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells,” Nature, vol. 486, no. 7404, pp. 549–553, 2012. Nature

[81] S. A. Lim, J. Wei, T.-L. M. Nguyen, H. Shi, W. Su, G. Palacios, Y. Dhungana, N. M. Chapman, L. Long, J. Saravia, P. Vogel, and H. Chi, “Lipid signalling enforces functional specialization of Treg cells in tumours,” Nature, vol. 591, no. 7849, pp. 306–311, 2021. Nature

[82] G. M. Delgoffe, T. P. Kole, Y. Zheng, P. E. Zarek, K. L. Matthews, B. Xiao, P. F. Worley, S. C. Kozma, J. D. Powell, and T. J. Curiel, “The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment,” Immunity, vol. 30, no. 6, pp. 832–844, 2009. ScienceDirect

[83] M. M. Mihaylova and R. J. Shaw, “The AMPK signalling pathway coordinates cell growth, autophagy and metabolism,” Nature Cell Biology, vol. 13, no. 9, pp. 1016–1023, 2011. Nature

[84] E. V. Dang, J. Barbi, H.-Y. Yang, D. Jinasena, H. Yu, Y. Zheng, Z. Bordman, J. Fu, Y. Kim, H.-R. Yen, W. Luo, K. Zeller, L. Shimoda, S. L. Topalian, G. L. Semenza, C. V. Dang, and D. M. Pardoll, “Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1,” Cell, vol. 146, no. 5, pp. 772–784, 2011. ScienceDirect

[85] E. T. Clambey, E. N. McNamee, J. A. Westrich, L. E. Glover, E. L. Campbell, P. Jedlicka, E. F. de Zoeten, J. C. Cambier, K. R. Stenmark, S. P. Colgan, and H. K. Eltzschig, “Hypoxia-inducible factor-1 alpha–dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 41, pp. E2784–E2793, 2012. PNAS

[86] R. Zappasodi, S. Budhu, M. D. Hellmann, M. A. Postow, and T. Merghoub, “Non-conventional Inhibitory CD4⁺Foxp3⁻ PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity,” Cancer Cell, vol. 39, no. 3, pp. 310–321, 2021. ScienceDirect

[87] S. Sakaguchi, N. Mikami, J. B. Wing, A. Tanaka, K. Ichiyama, and N. Ohkura, “Regulatory T cells and human disease,” Annual Review of Immunology, vol. 38, pp. 541–566, 2020. Annual Reviews

[88] J. Nie, Y.-Y. Li, S.-G. Zheng, A. Tsun, and B. Li, “FOXP3⁺ regulatory T cells and their roles in immune regulation,” Clinical and Experimental Immunology, vol. 172, no. 1, pp. 1–9, 2013. Wiley

[89] J. A. Bluestone, C. R. Mackay, J. J. O’Shea, and B. Stockinger, “The functional plasticity of T cell subsets,” Nature Reviews Immunology, vol. 10, no. 9, pp. 594–602, 2010. Nature

[90] M. Long, A. J. Adler, Z. Yao, C. S. Bonder, and X. Zhang, “CD4⁺CD25⁺Foxp3⁺ regulatory T cells promote tumor progression by suppressing antitumor immune responses,” Cancer Research, vol. 70, no. 5, pp. 185–192, 2010.

[91] J. A. Todd, “Etiology of type 1 diabetes,” Immunity, vol. 32, no. 4, pp. 457–467, 2010. ScienceDirect

[92] Q. Tang and J. A. Bluestone, “The Foxp3⁺ regulatory T cell: a jack of all trades, master of regulation,” Nature Immunology, vol. 9, no. 3, pp. 239–244, 2008. Nature

[93] M. Rosenzwajg, E. Languille, H. Debiec, J. Hygino, E. Dériaud, L. Moumne, M. Bonyhadi, G. Afonso, R. Bacchetta, and D. Klatzmann, “Transient regulatory T cells: a therapeutic approach for autoimmune diseases,” Journal of Translational Medicine, vol. 13, Art. no. 201, 2015. Springer

[94] M. Miyara and S. Sakaguchi, “Natural regulatory T cells: mechanisms of suppression,” Trends in Molecular Medicine, vol. 11, no. 8, pp. 367–372, 2005. ScienceDirect

[95] D. Comte, M. P. Karampetsou, and G. C. Tsokos, “T cells as a therapeutic target in autoimmune disease,” Current Opinion in Immunology, vol. 43, pp. 84–90, 2016. ScienceDirect

[96] J. He, X. Zhang, Y. Wei, X. Sun, Y. Chen, J. Deng, Y. Jin, Y. Gan, X. Hu, R. Jia, M. Zhang, Y. Shen, B. Wang, N. Li, L. Lv, Y. Li, X. Zhang, and Z. Li, “Low-dose interleukin-2 treatment selectively modulates CD4⁺ T cell subsets in patients with systemic lupus erythematosus,” Nature Medicine, vol. 22, no. 9, pp. 991–993, 2016. Nature

[97] V. Viglietta, C. Baecher-Allan, H. L. Weiner, and D. A. Hafler, “Loss of functional suppression by CD4⁺CD25⁺ regulatory T cells in patients with multiple sclerosis,” The Journal of Experimental Medicine, vol. 199, no. 7, pp. 971–979, 2004. JEM

[98] M. Kleinewietfeld and D. A. Hafler, “The emerging role of regulatory T cells in multiple sclerosis,” Immunological Reviews, vol. 259, no. 1, pp. 116–128, 2014. Wiley

[99] Y. Dombrowski, T. O’Hagan, M. Dittmer, R. Penalva, S. R. Mayoral, P. Bankhead, S. Fleville, G. Eleftheriadis, C. Zhao, M. Naughton, R. Hassan, J. Moffat, J. Falconer, A. Boyd, P. Hamilton, I. V. Allen, A. Kissenpfennig, P. N. Moynagh, E. Evergren, B. Perbal, A. C. Williams, R. J. Ingram, J. R. Chan, R. J. M. Franklin, and D. C. Fitzgerald, “Regulatory T cells promote myelin regeneration in the central nervous system,” Nature Neuroscience, vol. 20, no. 5, pp. 674–680, 2017. Nature

[100] S. Z. Josefowicz, L. F. Lu, and A. Y. Rudensky, “Regulatory T cells: mechanisms of differentiation and function,” Annual Review of Immunology, vol. 30, pp. 531–564, 2012. Annual Reviews

[101] S. Read, V. Malmström, and F. Powrie, “Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25⁺CD4⁺ regulatory cells that control intestinal inflammation,” The Journal of Experimental Medicine, vol. 192, no. 2, pp. 295–302, 2000. JEM

[102] E.-O. Glocker, D. Kotlarz, C. Klein, N. Shah, and B. Grimbacher, “IL-10 and IL-10 receptor defects in humans,” Annals of the New York Academy of Sciences, vol. 1166, pp. 18–34, 2009. Wiley

[103] H. Sugiyama, R. Gyulai, E. Toichi, E. Garaczi, S. Shimada, S. R. Stevens, T. S. McCormick, and K. D. Cooper, “Dysfunctional blood and target tissue CD4⁺CD25^high regulatory T cells in psoriasis: Mechanism underlying unrestrained pathogenic effector T cell proliferation,” The Journal of Immunology, vol. 174, no. 1, pp. 164–173, 2005. Journal of Immunology

[104] H. J. Bovenschen, P. C. van de Kerkhof, P. E. J. van Erp, R. Woestenenk, I. Joosten, and H. J. P. M. Koenen, “Foxp3⁺ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin,” Journal of Investigative Dermatology, vol. 131, no. 9, pp. 1853–1860, 2011. Nature

[105] M. S. Longhi, M. J. Hussain, R. R. Mitry, S. K. Arora, G. Mieli-Vergani, D. Vergani, and Y. Ma, “Functional study of CD4⁺CD25⁺ regulatory T cells in health and autoimmune hepatitis,” The Journal of Immunology, vol. 173, no. 11, pp. 6569–6577, 2004. Journal of Immunology

[106] J. B. Wing, A. Tanaka, and S. Sakaguchi, “Human FOXP3⁺ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer,” Immunity, vol. 50, no. 2, pp. 302–316, 2019. ScienceDirect

[107] Y. Togashi, K. Shitara, and H. Nishikawa, “Regulatory T cells in cancer immunosuppression—implications for anticancer therapy,” Nature Reviews Clinical Oncology, vol. 16, no. 6, pp. 356–371, 2019. Nature

[108] T. J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, Y. Zhu, S. Wei, I. Kryczek, B. Daniel, A. Gordon, L. Myers, A. Lackner, M. L. Disis, K. L. Knutson, L. Chen, and W. Zou, “Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival,” Nature Medicine, vol. 10, no. 9, pp. 942–949, 2004. Nature

[109] S. Sakaguchi, T. Yamaguchi, T. Nomura, and M. Ono, “Regulatory T cells and immune tolerance,” Cell, vol. 133, no. 5, pp. 775–787, 2008. ScienceDirect

[110] S. Z. Josefowicz, L. F. Lu, and A. Y. Rudensky, “Regulatory T cells: mechanisms of differentiation and function,” Annual Review of Immunology, vol. 30, pp. 531–564, 2012. Annual Reviews

[111] D. A. A. Vignali, L. W. Collison, and C. J. Workman, “How regulatory T cells work,” Nature Reviews Immunology, vol. 8, no. 7, pp. 523–532, 2008. Nature

[112] E. M. Shevach, “Mechanisms of foxp3⁺ T regulatory cell-mediated suppression,” Immunity, vol. 30, no. 5, pp. 636–645, 2009. ScienceDirect

[113] D. C. Gondek, L.-F. Lu, S. A. Quezada, S. Sakaguchi, and R. J. Noelle, “Cutting edge: Contact-mediated suppression by CD4⁺CD25⁺ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism,” The Journal of Immunology, vol. 174, no. 4, pp. 1783–1786, 2005. Journal of Immunology

[114] K. Wing, Y. Onishi, P. Prieto-Martin, T. Yamaguchi, M. Miyara, Z. Fehervari, T. Nomura, and S. Sakaguchi, “CTLA-4 Control over Foxp3⁺ Regulatory T Cell Function,” Science, vol. 322, no. 5899, pp. 271–275, 2008. Science

[115] O. S. Qureshi, Y. Zheng, K. Nakamura, K. Attridge, C. Manzotti, E. M. Schmidt, J. Baker, L. E. Jeffery, S. Kaur, Z. Briggs, T. Z. Hou, C. E. Futter, G. Anderson, L. S. K. Walker, and D. M. Sansom, “Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4,” Science, vol. 332, no. 6029, pp. 600–603, 2011. Science

[116] G. Plitas and A. Y. Rudensky, “Regulatory T Cells in Cancer,” Annual Review of Cancer Biology, vol. 1, pp. 459–477, 2016.

[117] T. R. Simpson, F. Li, W. Montalvo-Ortiz, M. A. Sepulveda, K. Bergerhoff, F. Arce, C. Roddie, J. Y. Henry, H. Yagita, J. D. Wolchok, K. S. Peggs, and S. A. Quezada, “Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma,” Journal of Experimental Medicine, vol. 210, no. 9, pp. 1695–1710, 2013. JEM

[118] P. Sharma and J. P. Allison, “The future of immune checkpoint therapy,” Science, vol. 348, no. 6230, pp. 56–61, 2015. Science

[119] K. E. Pauken, M. A. Sammons, P. M. Odorizzi, S. Manne, J. Godec, O. Khan, A. M. Drake, Z. Chen, D. R. Sen, M. Kurachi, R. A. Barnitz, C. Bartman, B. Bengsch, A. C. Huang, J. M. Schenkel, G. Vahedi, W. N. Haining, S. L. Berger, and E. J. Wherry, “Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade,” Science, vol. 354, no. 6316, pp. 1160–1165, 2016. Science

[120] P. C. Tumeh, C. L. Harview, J. H. Yearley, I. P. Shintaku, E. J. M. Taylor, L. Robert, B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, A. N. West, M. Carmona, C. Kivork, E. Seja, G. Cherry, A. J. Gutierrez, T. R. Grogan, C. Mateus, G. Tomasic, J. A. Glaspy, R. O. Emerson, H. Robins, R. H. Pierce, D. A. Elashoff, C. Robert, and A. Ribas, “PD-1 blockade induces responses by inhibiting adaptive immune resistance,” Nature, vol. 515, no. 7528, pp. 568–571, 2014. Nature

[121] T. J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, Y. Zhu, S. Wei, I. Kryczek, B. Daniel, A. Gordon, L. Myers, A. Lackner, M. L. Disis, K. L. Knutson, L. Chen, and W. Zou, “Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival,” Nature Medicine, vol. 10, no. 9, pp. 942–949, 2004. Nature

[122] B. Shang, Y. Liu, S.-J. Jiang, and Y. Liu, “Prognostic value of tumor-infiltrating FoxP3⁺ regulatory T cells in cancers: a systematic review and meta-analysis,” Scientific Reports, vol. 5, Art. no. 15179, 2015. Nature

[123] P. Salama, M. Phillips, F. Grieu, M. Morris, N. Zeps, D. Joseph, C. Platell, and B. Iacopetta, “Tumor-infiltrating FOXP3⁺ T regulatory cells show strong prognostic significance in colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 2, pp. 186–192, 2009. ASCO

[124] W. H. Fridman, F. Pagès, C. Sautès-Fridman, and J. Galon, “The immune contexture in human tumours: impact on clinical outcome,” Nature Reviews Cancer, vol. 12, no. 4, pp. 298–306, 2012. Nature

[125] R. D. Michalek, V. A. Gerriets, S. R. Jacobs, A. N. Macintyre, N. J. MacIver, E. F. Mason, S. A. Sullivan, A. G. Nichols, and J. C. Rathmell, “Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4⁺ T Cell Subsets,” The Journal of Immunology, vol. 186, no. 6, pp. 3299–3303, 2011. Journal of Immunology

[126] U. H. Beier, A. Angelin, T. Akimova, L. Wang, Y. Liu, H. Xiao, M. A. Koike, S. A. Hancock, T. R. Bhatti, R. Han, J. Jiao, S. C. Veasey, C. A. Sims, J. A. Baur, D. C. Wallace, and W. W. Hancock, “Essential role of mitochondrial energy metabolism in Foxp3⁺ T-regulatory cell function and allograft survival,” FASEB Journal, vol. 29, no. 6, pp. 2315–2326, 2015. FASEB

[127] Pacella, C. Procaccini, C. Focaccetti, S. Miacci, E. Timperi, D. Faicchia, M. Severa, F. Rizzo, E. M. Coccia, F. Bonacina, N. Mitro, G. D. Norata, G. Rossetti, V. Ranzani, M. Pagani, E. Giorda, Y. Wei, G. Matarese, V. Barnaba, and S. Piconese, “Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth,” Proceedings of the National Academy of Sciences of the United States of America (PNAS), vol. 115, no. 28, pp. E6546–E6555, 2018. PNAS

[128] G. M. Delgoffe, T. P. Kole, Y. Zheng, P. E. Zarek, K. L. Matthews, B. Xiao, P. F. Worley, S. C. Kozma, J. D. Powell, and T. J. Curiel, “The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment,” Immunity, vol. 30, no. 6, pp. 832–844, 2009. ScienceDirect

[129] S. Onizuka, I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama, “Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody,” Cancer Research, vol. 59, no. 13, pp. 3128–3133, 1999.

[130] T. R. Simpson, F. Li, W. Montalvo-Ortiz, M. A. Sepulveda, K. Bergerhoff, F. Arce, C. Roddie, J. Y. Henry, H. Yagita, J. D. Wolchok, K. S. Peggs, and S. A. Quezada, “Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma,” The Journal of Experimental Medicine, vol. 210, no. 9, pp. 1695–1710, 2013. JEM

[131] B. Allard, M. S. Longhi, S. C. Robson, and J. Stagg, “The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets,” Immunological Reviews, vol. 276, no. 1, pp. 121–144, 2017. Wiley

[132] G. Plitas, C. Konopacki, K. Wu, P. D. Bos, M. Morrow, E. V. Putintseva, D. M. Chudakov, and A. Y. Rudensky, “Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer,” Immunity, vol. 45, no. 5, pp. 1122–1134, 2016. ScienceDirect

[133] Giannopoulos, M. Schmitt, P. Wlasiuk, J. Chen, A. Bojarska-Junak, M. Kowal, A. Dmoszyńska, and J. Rolinski, “The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide,” Leukemia, vol. 22, no. 1, pp. 222–224, 2009.

[134] N. A. Marshall, L. E. Christie, L. R. Munro, D. J. Culligan, P. W. Johnston, R. N. Barker, and M. A. Vickers, “Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma,” Blood, vol. 103, no. 5, pp. 1755–1762, 2004. Blood

[135] R. H. Prabhala, P. Neri, J. E. Bae, P. Tassone, M. A. Shammas, C. K. Allam, J. F. Daley, D. Chauhan, E. Blanchard, H. S. Thatte, K. C. Anderson, and N. C. Munshi, “Dysfunctional T regulatory cells in multiple myeloma,” Blood, vol. 107, no. 1, pp. 301–304, 2006. Blood

[136] S. Ladoire, L. Arnould, G. Mignot, L. Apetoh, C. Rébé, F. Martin, B. Chauffert, and F. Ghiringhelli, “Presence of Foxp3 expression in tumor-infiltrating lymphocytes is associated with better prognosis in breast cancer: a rationale for immune-based therapies,” Cancer Research, vol. 71, no. 8, pp. 3076–3087, 2011. AACR

[137] S. Karanika, T. Karantanos, L. Li, P. G. Corn, and T. C. Thompson, “Systematic review and meta-analysis of the prognostic significance of PD-L1 expression and tumor-infiltrating lymphocytes in genitourinary malignancies,” European Urology, vol. 68, no. 4, pp. 701–710, 2015. ScienceDirect

[138] B. Shang, Y. Liu, S.-J. Jiang, and Y. Liu, “Prognostic value of tumor-infiltrating FoxP3⁺ regulatory T cells in cancers: a systematic review and meta-analysis,” Scientific Reports, vol. 5, Art. no. 15179, 2015. Nature

[139] P. Salama, M. Phillips, F. Grieu, M. Morris, N. Zeps, D. Joseph, C. Platell, and B. Iacopetta, “Tumor-infiltrating FOXP3⁺ T regulatory cells show strong prognostic significance in colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 2, pp. 186–192, 2009. ASCO

[140] C.-X. Li, C.-C. Ling, Y. Shao, A. Xu, X.-C. Li, K. T.-P. Ng, X. B. Liu, Y.-Y. Ma, X. Qi, H. Liu, J. Liu, W. H. O. Yeung, C. M. Lo, K. Man, and Y. Ma, “CXCL10/CXCR3 signaling mobilizes regulatory T cells to promote hepatocellular carcinoma progression,” Journal of Hepatology, vol. 62, no. 4, pp. 950–959, 2015. ScienceDirect

[141] E. M. Aandahl, J. Michaëlsson, W. J. Moretto, F. M. Hecht, and D. F. Nixon, “Human CD4⁺CD25⁺ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens,” Journal of Virology, vol. 78, no. 5, pp. 2454–2459, 2004. ASM

[142] A. L. Kinter, R. Horak, M. Sion, L. Riggin, J. McNally, Y. Lin, R. Jackson, A. O'Shea, G. Roby, C. Kovacs, M. Connors, and A. S. Fauci, “CD25⁺ regulatory T cells isolated from HIV-infected individuals suppress the cytolytic and nonlytic antiviral activity of HIV-specific CD8⁺ T cells in vitro,” AIDS Research and Human Retroviruses, vol. 23, no. 3, pp. 438–450, 2007. Mary Ann Liebert

[143] N. Seddiki, B. Santner-Nanan, J. Martinson, J. Zaunders, S. Sasson, A. Landay, M. Solomon, W. Selby, S. I. Alexander, R. Nanan, A. Kelleher, and B. F. de St. Groth, “Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells,” The Journal of Experimental Medicine, vol. 203, no. 7, pp. 1693–1700, 2006. JEM

[144] O. Franzese, P. T. F. Kennedy, A. J. Gehring, J. Gotto, R. Williams, M. K. Maini, and A. Bertoletti, “Modulation of the CD8⁺ T-cell response by CD4⁺CD25⁺ regulatory T cells in patients with hepatitis B virus infection,” Journal of Virology, vol. 79, no. 6, pp. 3322–3328, 2005. ASM

[145] E. Stephen-Victor and M. Das, “Regulatory T Cells: The Master Regulators of Immune Responses,” Frontiers in Immunology, vol. 11, Art. no. 598, 2020. Frontiers

[146] G. Minigo, T. Woodberry, K. A. Piera, E. Salwati, E. Tjitra, E. Kenangalem, R. N. Price, C. R. Engwerda, N. M. Anstey, and M. Plebanski, “Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria,” PLoS Pathogens, vol. 5, no. 4, Art. no. e1000402, 2009. PLOS

[147] S. Sakaguchi, M. Miyara, C. M. Costantino, and D. A. Hafler, “FOXP3⁺ regulatory T cells in the human immune system,” Nature Reviews Immunology, vol. 10, no. 7, pp. 490–500, 2010. Nature

[148] P. C. Tumeh, C. L. Harview, J. H. Yearley, I. P. Shintaku, E. J. M. Taylor, L. Robert, B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, A. N. West, M. Carmona, C. Kivork, E. Seja, G. Cherry, A. J. Gutierrez, T. R. Grogan, C. Mateus, G. Tomasic, J. A. Glaspy, R. O. Emerson, H. Robins, R. H. Pierce, D. A. Elashoff, C. Robert, and A. Ribas, “PD-1 blockade induces responses by inhibiting adaptive immune resistance,” Nature, vol. 515, no. 7528, pp. 568–571, 2014. Nature

[149] E. M. Aandahl, J. Michaëlsson, W. J. Moretto, F. M. Hecht, and D. F. Nixon, “Human CD4⁺CD25⁺ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens,” Journal of Virology, vol. 78, no. 5, pp. 2454–2459, 2004. ASM

[150] N. Seddiki, B. Santner-Nanan, J. Martinson, J. Zaunders, S. Sasson, A. Landay, M. Solomon, W. Selby, S. I. Alexander, R. Nanan, A. Kelleher, and B. F. de St. Groth, “Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells,” The Journal of Experimental Medicine, vol. 203, no. 7, pp. 1693–1700, 2006. JEM

[151] Pacella, C. Procaccini, C. Focaccetti, S. Miacci, E. Timperi, D. Faicchia, M. Severa, F. Rizzo, E. M. Coccia, F. Bonacina, N. Mitro, G. D. Norata, G. Rossetti, V. Ranzani, M. Pagani, E. Giorda, Y. Wei, G. Matarese, V. Barnaba, and S. Piconese, “Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth,” Proceedings of the National Academy of Sciences of the United States of America, vol. 115, no. 28, pp. E6546–E6555, 2018. PNAS

[152] S. Z. Josefowicz, L. F. Lu, and A. Y. Rudensky, “Regulatory T cells: mechanisms of differentiation and function,” Annual Review of Immunology, vol. 30, pp. 531–564, 2012. Annual Reviews

@article{1723380,
      author = {Augustine Chimdindu Igwe, Nkiruka Rose Ukibe, Samuel Chukwuemeka Meludu},
      title = {Regulatory T Cells in Immune Homeostasis: Mechanisms of Peripheral Tolerance and Immunoregulation},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {10},
      number = {3},
      pages = {3201-3234},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1723380.pdf},
      abstract = {Regulatory T cells (Tregs) are specialized subsets of T lymphocytes that maintain immune tolerance, suppress excessive immune responses, and preserve immune homeostasis. These cells are essential for preventing autoimmunity, controlling inflammation, and modulating immune responses during infection, cancer, and transplantation. The transcription factor Forkhead box P3 (FOXP3) serves as the master regulator of Treg development and function, while cytokines such as interleukin-10 (IL-10), transforming growth factor-beta (TGF-β), and interleukin-35 (IL-35) mediate their suppressive activities. Recent advances have revealed substantial heterogeneity among Treg populations, including thymus-derived and peripheral Tregs, tissue-resident Tregs, and memory-like Tregs. Dysregulation of Treg number or function contributes significantly to autoimmune diseases, chronic inflammatory conditions, infections, and tumor progression. Furthermore, emerging therapeutic approaches targeting Tregs, including low-dose IL-2 therapy and chimeric antigen receptor Treg (CAR-Treg) therapy, are gaining clinical importance. This review discusses the biology, classification, molecular mechanisms, suppressive pathways, and clinical significance of Tregs in immune homeostasis and disease.},
      keywords = {Regulatory T cells, FOXP3, immune tolerance, immune homeostasis, cytokines, IL-10, TGF-β, CTLA-4, immunoregulation},
      month = {September},
      doi = {https://doi.org/10.64388/IREV10I3-1723380}
  }